- Policy
- COVID-19 Special Committee announced a“Pincette Meeting”
- by Lee, Jeong-Hwan Mar 5, 2020 06:34am
- The National Assembly's COVID-19 Countermeasures Special Committee is the first to resolve the issue of 'Daegu hospital bed & medical facilities shortage' and 'mask shortages' and will hold a 'Pincette Meeting' for about 4 hours. The committee decided to receive a report on issues related to the lack of mask supply to the MFDS, the Ministr
- Policy
- Remdesivir, clinical trial of 195 patients with COVID-19
- by Lee, Tak-Sun Mar 5, 2020 06:33am
- Gilead Science's 'Remdesivir', which is attracting attention as a treatment for COVID-19, is conducting clinical trials on a total of 195 patients in Korea. There are three medical institutions with clinical trials: Kyungpook National University Hospital, National Medical Center, and Seoul Medical Center. The Ministry of Food and Drug S
- Company
- 86% of generics for erectile dysfunction are domestic
- by Chon, Seung-Hyun Mar 5, 2020 06:33am
- The sales rate of generic products developed in Korea in the erectile dysfunction market is very high. Hanmi pharm's Palpal is one of hottest items, and Chong Kun Dang's Cendom continued to rise. Domestically developed drugs account for 86% of the erectile dysfunction drug market, and the influence of domestic products is expanding. According
- Company
- Janssen Korea breaks through KRW 300 bln for the first time
- by An, Kyung-Jin Mar 5, 2020 06:33am
- Janssen Korea broke through the 300 billion won-line in Korea for the first time. Leveraged by outstanding performance of star products like Remicade, Simponi and Stelara, the global pharmaceutical company manifested impressive sales revenue and operating profit. According to performance data of last fourth quarter provided by Yuhan on
- Company
- Boryung Bio releases 'self-sufficient' quadrivalent vaccine
- by An, Kyung-Jin Mar 5, 2020 06:33am
- On Mar. 2, Boryung Biopharma announced the release of ‘Boryung DTaP-IPV Vaccine’ for infants and children. ‘Boryung DTaP-IPV Vaccine’ is a quadrivalent vaccine consisting of DTaP vaccines preventing diphtheria, tetanus and pertussis and inactivated polio vaccine (IPV) against poliomyelitis. Total six doses is required when administer
- Chronic illness was fatal for COVID-19 infected patients
- by park-sangjun Mar 4, 2020 06:28am
- The number of deaths in COVID-19 in Korea increased to 28, with fatal underlying disease. Much attention should be paid, especially if having heart disease and diabetes. Investigating the characteristics of 28 deaths (as of March 3, 00:00) announced by the KCDC, most of the unhealthy patients, such as decreased immune function in old age,
- Company
- BMS-Celgene merger restructures Korean office
- by Eo, Yun-Ho Mar 4, 2020 06:27am
- The basic frame of Bristol-Myers Squibb (BMS) and Celgene’s merger company has been unveiled. Recently, BMS presented a newly formed division and appointed the head of Business Unit for the merger. The Commercial Business Unit, including marketing and sales, would undergo the biggest change. BMS has decided to integrate BMS’ existi
- Company
- Whan In has signed domestic monopoly rights of 'Cariprazine'
- by Jung, Hye-Jin Mar 4, 2020 06:27am
- Whan In Pharm (CEO Won-bum Lee) announced on the 2nd that it has signed an exclusive contract to introduce Cariprazine, a schizophrenic drug from Gedeon Richter, Hungary. Under this contract, Whan In Pharm is responsible for commercializing, distributing and selling products such as domestic clinical trials and product approval of Caripraz
- Product
- Panic buying Tylenol-Advil in fear of COVID-19 fake news
- by Jung, Heung-Jun Mar 4, 2020 06:27am
- Tylenol and Advil are out of stock as their demands have skyrocketed due to online fake news encouraging panic buying of OTC drugs and claiming the Korean government’s containment of COVID-19 has failed. On Mar. 2, a multiple online pharmacies have posted notice on shortage of Tylenol, Advil and Aspirin. Apparently, the circulating
- Company
- In the aftermath of the COVID-19, the BA test was disrupted
- by Chon, Seung-Hyun Mar 4, 2020 06:27am
- COVID-19 infections have also influenced the generic development strategies of pharmaceutical companies. Due to the risk of infection with COVID-19, the bioequivalence task of medical institutions has been disrupted. This is an embarrassing situation for pharmaceutical companies that are conducting bioequivalence tests to reduce drug prices a
